As of Friday close, Amneal Pharmaceuticals Inc.’s (NYSE:AMRX) stock was down -$0.28, moving down -8.09 percent to $3.18. The average number of shares traded per day over the past five days has been 832,700 shares. 4 times new highs have been achieved over the past 5 days, with a -$0.36 fall in that time frame. In the last twenty days, the average volume was 636,610, while in the previous 50 days, it was 663,548.
Since last month, AMRX stock retreated -3.34%. Shares of the company fell to $3.05 on 07/15/22, the lowest level in the past month. A 52-week high of $5.99 was reached on 01/05/22 after having rallying from a 52-week low of $2.90. Since the beginning of this year, AMRX’s stock price has dropped by -33.61% or -$1.61, and marked a new high 3 times. However, the stock has declined by -46.91% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Amneal Pharmaceuticals Inc. (AMRX) last reported insider trading activity 232 days ago on Dec 17. Patel Gautam, the Director of the company, purchased of 50,000 shares for $4.21 on Dec 17. It resulted in a $210,500 investment by the insider. Patel Chintu added 50,000 shares at an average price of $4.25 on Dec 16. The insider now owns 512,566 shares following the transaction. On Dec 16, President & Co-CEO Patel Chirag K. bought 50,000 shares at $4.25 apiece. The transaction was valued at $212,500.
Right now, Amneal Pharmaceuticals Inc. (AMRX) has a P/E ratio of about 318.00. The stock’s beta is 1.19. Besides these, the trailing price-to-sales (P/S) ratio of 0.46, the price-to-book (PB) ratio of 1.22, and the price-to-cash flow ratio of 4.62 may also be considered.
In the three months ended March 30, Amneal Pharmaceuticals Inc.’s quick ratio stood at 1.50, while its current ratio was 2.30, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 7.09, and the total debt-to-equity ratio was 7.17. On the profitability front, the trailing twelve-month gross margin is 36.90% percent. In the year ended March 30, operating margins totaled 6.20%. Based on annual data, AMRX earned $768.97 million in gross profit and brought in $2.09 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 4.50%. Return on equity (ROE) for the past 12 months was 0.50%.
In Amneal Pharmaceuticals Inc.’s quarter-end financial report for March 30, it reported total debt of $2.67 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. AMRX’s revenue rose 0.91% to $514.89 million during the quarter, while net income inched up to $497.63 million. While analysts expected Amneal Pharmaceuticals Inc. to report $0.13 quarterly earnings, the actual figure was $0.12 per share, beating the consensus estimate by -7.70%. During the quarter, the company generated $83.52 million in EBITDA. The liabilities of Amneal Pharmaceuticals Inc. were 3.48 billion at the end of its most recent quarter ended March 30, and its total debt was $2.87 billion. The value of shareholders’ equity is $302.92 million.
This quick technical analysis looks at Amneal Pharmaceuticals Inc.’s (AMRX) price momentum. With a historical volatility rate of 58.79%, the RSI 9-day stood at 36.03% on 05 August.
With respect to its five-day moving average, the current Amneal Pharmaceuticals Inc. price is down by -10.17% percent or -$0.36. At present, AMRX shares trade -3.64% below its 20-day simple moving average and -21.48% percent below its 100-day simple moving average. However, the stock is currently trading approximately -3.64% below its SMA50 and -43.92% below its SMA200.
Stochastic coefficient K was 55.48% and Stochastic coefficient D was 74.95%, while ATR was 0.20. Given the Stochastic reading of 19.08% for the 14-day period, the RSI (14) reading has been calculated as 42.05%. As of today, the MACD Oscillator reading stands at -0.08.
Amneal Pharmaceuticals Inc. (AMRX) has been rated Overweight by analysts. According to 1 brokerage firm, AMRX is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Amneal Pharmaceuticals Inc. stock as buy, with 3 recommending it as overweight.
With a median target price of $6.00, the current consensus forecast for the stock is $4.50 – $7.00. Based on these forecasts, analysts predict Amneal Pharmaceuticals Inc. (AMRX) will achieve an average price target of $5.90.